Heart failure and chronic kidney disease: An integrated care approach

Journal of Renal Care

Volumn 36, Issue SUPPL. 1, 2010, Pages 127-135

  Jenkins, Karen ^a   Kirk, Mary ^a  

^a UNIVERSITY OF KENT   (United Kingdom)

Author keywords

Cardio renal syndrome risk management; Chronic kidney disease; Heart failure

Indexed keywords

ARTICLE; CHRONIC KIDNEY FAILURE; COOPERATION; HEART FAILURE; HUMAN; INTERDISCIPLINARY COMMUNICATION; MORTALITY; MULTIMODALITY CANCER THERAPY; NURSING; PATIENT CARE; RISK FACTOR; SURVIVAL RATE;

COMBINED MODALITY THERAPY; COOPERATIVE BEHAVIOR; HEART FAILURE; HUMANS; INTERDISCIPLINARY COMMUNICATION; KIDNEY FAILURE, CHRONIC; PATIENT CARE TEAM; RISK FACTORS; SURVIVAL RATE;

EID: 77952574519     PISSN: 17556678     EISSN: 17556686     Source Type: Journal    
DOI: 10.1111/j.1755-6686.2010.00158.x     Document Type: Article

References (39)

1. Bisoprolol Study (1999). The cardiac insufficiency Bisoprolol study II (CIBIS II): a randomised control trial. Lancet 353 (9146 9 13.
2. Brenner B.M., Cooper M.E., de Zeeuw D. et al 2001). RENAAL Study investigators. Effects of Losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. New England Journal of Medicine 354, 861 869.
3. British Heart Foundation (2002). Coronary heart disease statistics: heart failure supplement. Available from : http://www.heartstats.org.uk (accessed January 10).
4. Brown J., Uber P. Mehra M. (2008). The progressive cardio renal syndrome in heart failure: mechanisms and therapeutic insights: current treatment options. Cardiovascular Medicine 10 (4 342 348.
5. Chamberlain I. Obialo M.D. (2007). Cardio renal consideration as a risk for heart failure. American Journal of Cardiology 99 (suppl 21D 24D.
6. Cohen-Solal A., Kotecha D., Van Veldhuisen D. et al 2009). Efficacy and safety of nebivolol in elderly heart failure patients with impaired renal function: insights from the SENIORS trial. European Journal of Heart Failure 11, 872 880.
7. Cowie M. Zaphiriou A. (2002). Management of chronic heart failure. British MedicalJournal 325, 422 425.
8. Department of Health (2000). National Service Framework for Coronary Heart Disease. Available from : http://www.dh.gov.uk/en/ Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH-4094275 (accessed January 2010).
9. Effects of Enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD investigators. New England Journal of Medicine 1991, 325 (5 293 302.
10. European society of cardiology (ESC) guidelines for the diagnosis and treatment of acute and chronic heart failure (2008). European Heart Journal 29, 2388 2442. Available from : http://www.escardio.org/guidelines-surveys/ escguidelines/GuidelinesDocuments/guidelines (accessed January 2010).
11. Flather M., Shibata M., Coats A. et al. On behalf of the SENIORS Investigators (2005). Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). European Heart Journal 26, 215 225.
12. Geisberg C, Butler J 2006). Addressing the challenges of cardio renal syndrome cleve. Clinical Journal of Medicine 73, 485 491.
13. Goodman W.G. London G. On behalf of the Vascular Calcification Work Group (2004). Vascular clacification in chronic kidney disease. American Journal of Kidney Diseases 43 (3 572 579.
14. Hjalmarson A., Goldstein S., Fageberg B. et al 2000). MERIT HF: effects of controlled release metoprolol on total mortality, hospi-talisation, and well being in patients with heart failure: the metoprolol CR/XL Randomised Intervention trial in congestive heart failure (MERIT HF) MERIT HF study group. Journal of the American Medical Association (JAMA) 283 (10 1295 1302.
15. Ismailov R., Goldberg R., Lessard D. et al 2007). Decompensated heart failure in the setting of kidney dysfunction: a community wide perspective. Nephron Clinical Practice 107, 147 155.
16. Kidney Dialysis Outcome Quality Initiative (KDOQI) (2009). Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease. Available from : http://www.kidney.org/profes-sionals/KDOQI/guidelines-bone/ (accessed January 2010).
17. Keith D.S., Nichols G.A., Gullion CM. et al 2004). Longitudinal follow up and outcomes among a population with chronic kidney disease in a large managed care organization. Archives of Internal Medicine 164, 659 663.
18. Latini R., Masson S., Anand I. et al 2002). Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Val-HeFT trial. Circulation 106, 2454 2458.
19. Levin A., Thompson C.R., Ethier J. et al 1999). Left ventricular mass index increases in early renal disease: impact of decline in haemoglobin. American Journal of Kidney Disease 34, 125 134.
20. Magnus P. Beaglehole R. (2001). The real contribution of the major risk factors to the coronary epidemic. Archives of Internal Medicine 161 (22 2657 2660.
21. Mancia G., De Baker G., Domaniczak A. et al 2007). The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). European Heart Journal 28, 1462 1536.
22. Mann J.F, Gerstein H.C., Pogue J. et al 2001). Renal Insufficiency as a predictor of cardiovascular outcomes and impact of ramipril: the HOPE randomised trial. Annals of Internal Medicine 134, 629 636.
23. McAlister FA., Ezekowitz J., Tonelli M. et al 2004). Renal Insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study. Circulation 109, 1004 1009.
24. National Collaborating Centre for Chronic Conditions (NICE) 2006). Anaemia management in chronic kidney disease; national clinical guidance for management in adults and children.
25. National Collaborating Centre for Chronic Conditions (NICE) 2008). Chronic kidney disease: National clinical guideline for early identification and management in adults in primary and secondary care.
26. National Institute of Clinical Excellence Chronic Heart Failure (NICE) 2003). National Clinical Guideline for Diagnosis and Management in primary and secondary care. No. 5
27. National Institute of Clinical Excellence Chronic Heart Failure National Clinical Guideline for Diagnosis and Management in primary and secondary care. Guideline 2004 No. 5
28. National Kidney Foundation Kidney Dialysis Outcome Quality Initiative (NKF-K/DOQI) Guideline 15. Association of Chronic Kidney Disease with Cardiovascular disease 2006. Available from : http://www.kidney.org/ professionals/kdoqi/guidelines-ckd/p7-riskg15.htm (accessed December 2009).
29. Petersen S., Rayner M. Wolstenholme J. et al 2002). Coronary Heart Disease Statistics: Heart Failure Supplement. British Heart Foundation
30. Petrie C. Mark P. Weir R. (2008). Broken pump or leaky filter? Renal dysfunction in heart failure a contemporary review. International Journal of Cardiology 128, 154 165.
31. Pitt B., Zannad F, Remme W. et al 1999). The effect of spironolactone on morbidity and mortality in patients with severe heart failure for the Randomized Aldactone Evaluation Study (RALES) Investigators. The New England Journal of Medicine 341 (10 709 717.
32. Rakhit D., Marwick T., Armstrong K. et al 2006). Effect of aggressive risk factor modification on cardiac events and myocardial ischemia in patients with CKD. Heart 92, 1402 1408.
33. nd edition) 2002 Palgrave
34. Saltzman H., Sharma K., Mather P. et al 2007). Renal dysfunction in heart failure patients: what is the evidence? Heart Failure Review 12, 37 47.
35. Scottish intercollegiate guidelines network (SIGN) (2007). Management of chronic heart failure: a national clinical guideline. Available from : http://www.sign.ac.uk/pdf/sign95.pdf (accessed January 2010).
36. Silverberg D.S., Wexler D., Blum M. et al 2000). The use of subcutaneous and intravenous iron for the treatment of the anemia of severe resistant congestive cardiac failure improves cardiac and renal functional cardiac class and markedly reduces hospitalization. Journal of American College of Cardiology 35, 1737 1744.
37. Swedberg K., Pfeffer M., Granger C. et al 1999). Candesartan in heart failure - assessment of reduction in mortality and morbidity (CHARM): rationale and design. CHARM-Programme Investigators. Journal of Cardiac Failure 5, 276 282.
38. Tanasescu M., Leitzman M., Rimm E. et al 2002). Exercise type and intensity in relation to coronary heart disease in men. The Journal of the American Medical Association (JAMA) 288, 1994 2000.
39. Yusuf S., Hawken S., Ounpuu S. et al 2004). Effect of potentially modifiable risk factors associated with myocardial infraction in 52 countries. The interheart study. Lancet 364 (9438 937 952.